Skip to main content
Clinical Trials/NCT04738474
NCT04738474
Completed
Not Applicable

Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease

University of Washington1 site in 1 country78 target enrollmentMarch 15, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congenital Heart Disease
Sponsor
University of Washington
Enrollment
78
Locations
1
Primary Endpoint
Feasibility of Enrollment
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The purpose of this study is to evaluate the feasibility and preliminary efficacy of the Promoting Resilience in Stress Management (PRISM) intervention in patients with adult congenital heart disease.

Detailed Description

After consent is obtained, eligible patients (moderate or complex ACHD, stages B, C, or D) will complete the baseline study measures assessment and be randomized to receive PRISM or usual care (anticipated n=86, 43 per group). Patients in the intervention group will participate in the six PRISM sessions over 3 months. At 3 months following enrollment, patients in both groups will again complete study measures. We will define feasibility as a) the proportion of eligible patients who enroll and b) the proportion of patients who complete the intervention among those randomized to intervention. We will define preliminary efficacy as the change in mean resilience from baseline to 3 months after randomization between those randomized to intervention and usual care. Exploratory analyses will examine PRISM's impact on patient-centered outcomes of quality of life, symptoms of anxiety and depression, and perceived competence for health care.

Registry
clinicaltrials.gov
Start Date
March 15, 2023
End Date
July 25, 2024
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jill Steiner

Assistant Professor, School of Medicine

University of Washington

Eligibility Criteria

Inclusion Criteria

  • adults with moderate or complex ACHD, stages B, C, or D as defined by the 2018 ACHD guidelines
  • receive care in our health system

Exclusion Criteria

  • diagnosis of another life-limiting illness
  • inability to participate in study activities independently and in English

Outcomes

Primary Outcomes

Feasibility of Enrollment

Time Frame: 3 months

The proportion of patients who enroll in the study among those eligible during the recruitment period

Feasibility of PRISM

Time Frame: 3 months

The proportion of patients who complete the PRISM intervention among those randomized to intervention.

Secondary Outcomes

  • Mean Resilience(3 months)

Study Sites (1)

Loading locations...

Similar Trials